

PRESS RELEASE  
12 April 2017



## Annual Report 2016

**Lund, Sweden – 12 April 2017** – BioInvent International AB (OMXS: BINV) today announces that the Annual Report for 2016 now is available at the company's website, [www.bioinvent.com](http://www.bioinvent.com).

### **Notes to editors:**

#### **About BioInvent**

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company's clinical programmes are BI-1206, currently in a Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia and TB-403, in cooperation with Oncurios, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. In December 2016, the Company signed a strategic research collaboration with Pfizer Inc. BioInvent also works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late-stage clinical trials.

### **For further information, please contact:**

Michael Oredsson  
President and CEO  
+46 (0)46 286 85 67  
+46 (0)707 16 89 30  
[michael.oredsson@bioinvent.com](mailto:michael.oredsson@bioinvent.com)

#### **BioInvent International AB (publ)**

Co. reg. No. 556537-7263  
Visiting address: Sölvegatan 41  
Mailing address: 223 70 LUND  
Phone: +46 (0)46 286 85 50  
[www.bioinvent.com](http://www.bioinvent.com)

*The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.*

*This information is information that BioInvent International AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 12.30 p.m. CET, on 12 April, 2017.*